Abstract
Moexipril is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor. It is used for treatment of arterial hypertension. Moexipril is the prodrug, yielding moexiprilat by hydrolysis of an ethyl ester group. Moexiprilat is the metabolite responsible for the pharmacological effect after moexipril administration. Samples of rat and human microsomai preparations exposed to moexipril treatment were analyzed by HPLC using octyl silica stationary phase and isocratic elution. To detect moexipril and moexiprilat the separation was monitored by both ultraviolet and mass specific detection. The rat liver microsomal preparation was more effective to in producing moexiprilat than the similar one derived from human liver cell lines. While additional potential metabolites of moexipril were suggested by computer-modeling, moexiprilat was the sole metabolite detected after microsomal treatment.
Keywords: Moexipril metabolism, moexiprilat, microsomal, HPLC-ES-MS, isocratic elution
Medicinal Chemistry
Title: Metabolism of Moexipril to Moexiprilat: Determination of In Vitro Metabolism Using HPLC-ES-MS
Volume: 3 Issue: 1
Author(s): H. Kalasz, G. Petroianu, K. Tekes, I. Klebovich, K. Ludanyi and Zs. Gulyas
Affiliation:
Keywords: Moexipril metabolism, moexiprilat, microsomal, HPLC-ES-MS, isocratic elution
Abstract: Moexipril is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor. It is used for treatment of arterial hypertension. Moexipril is the prodrug, yielding moexiprilat by hydrolysis of an ethyl ester group. Moexiprilat is the metabolite responsible for the pharmacological effect after moexipril administration. Samples of rat and human microsomai preparations exposed to moexipril treatment were analyzed by HPLC using octyl silica stationary phase and isocratic elution. To detect moexipril and moexiprilat the separation was monitored by both ultraviolet and mass specific detection. The rat liver microsomal preparation was more effective to in producing moexiprilat than the similar one derived from human liver cell lines. While additional potential metabolites of moexipril were suggested by computer-modeling, moexiprilat was the sole metabolite detected after microsomal treatment.
Export Options
About this article
Cite this article as:
Kalasz H., Petroianu G., Tekes K., Klebovich I., Ludanyi K. and Gulyas Zs., Metabolism of Moexipril to Moexiprilat: Determination of In Vitro Metabolism Using HPLC-ES-MS, Medicinal Chemistry 2007; 3 (1) . https://dx.doi.org/10.2174/157340607779317490
DOI https://dx.doi.org/10.2174/157340607779317490 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug-Induced Anemia and Other Red Cell Disorders: A Guide in the Age of Polypharmacy
Current Clinical Pharmacology Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy
Current Medicinal Chemistry Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Editorial (Thematic issue: Possible Therapeutic Targets for the Treatment of Diabetic Retinopathy: Evidences from Experimental Models)
Current Clinical Pharmacology Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Editorial (Hot Topic: Flavoproteins and Flavoenzymes with Biomedical and Therapeutic Impact)
Current Pharmaceutical Design Application of Dual-Source CT Coronary Angiography in Type 2 Diabetic Patients with Symptomatic Coronary Heart Disease
Current Vascular Pharmacology Thyrotoxic Periodic Paralysis: A Concise Review of the Literature
Current Rheumatology Reviews Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Leptin-Induced Sympathetic Nerve Activation: Signaling Mechanisms and Cardiovascular Consequences in Obesity
Current Hypertension Reviews Pharmacotherapeutic Approach to Prevent or Treat Chronic Allograft Nephropathy
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design Comparison of Amniotic Fluid Index and Single Deepest Vertical Pocket
Current Women`s Health Reviews Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Kidney Injury
Recent Patents on Biomarkers Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design